Bristol buys Cafcit
Executive Summary
Bristol-Myers Squibb subsidiary Mead Johnson purchases Cafcit (caffeine citrate) from OPR Development. Cafcit is only drug approved for short-term (10-12 days) treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age, Bristol says...